General Medicine,ISSN:1311-1817, VOLUME 26 ISSUES 3, Page: 1339-1347
Journal link: https://general-medicine.org
Abstract Link: https://general-medicine.org/abstract-12-12-1339-1347/
december 2024

Exploring the relationship between occurrence of dyslipidemia and type 2 diabetes: a longitudinal study

[1]Dr Khaliqa Fatima, [2]Dr Rabbia Mehboob, [3]Atia Ashfaq, [4]Dr Tehreem Akhtar, [5]Dr Faiza Diaz, [6]Dr Iram Mumtaz, [7]Kashif Lodhi

[1]Akhtar saeed trust hospital Lahore
[2]Hospital is Divisional Headquarters Teaching Hospital Mirpur Azad Kashmir
[3]Azad Jammu and Kashmir Medical College Muzaffarabad.
[4]Hospital is Divisional Headquarters Teaching Hospital Mirpur Azad Kashmir
[5]Poonch medical college Rawalakot
[6]Hospital is Divisional Headquarters Teaching Hospital Mirpur Azad Kashmir
[7]Department of Agricultural, Food and Environmental Sciences. Università Politécnica delle Marche Via Brecce Bianche 10, 60131 Ancona (AN) Italy

ABSTRACT:

Background: Dyslipidemia and type 2 diabetes are two interrelated metabolic disorders with significant health implications. Understanding their relationship over time is crucial for effective management and prevention strategies. However, longitudinal studies exploring this relationship are limited.

Aim: This study aimed to investigate the longitudinal relationship between the occurrence of dyslipidemia and type 2 diabetes over a period of one year.

Methods: A longitudinal study was conducted involving a study population of 90 individuals. Participants were recruited from May 2023 to April 2024. Baseline assessments were conducted to determine the presence of dyslipidemia and type 2 diabetes using standardized diagnostic criteria. Follow-up assessments were carried out at regular intervals over the study duration to track the occurrence and progression of both conditions.

Results: Analysis of the longitudinal data revealed a significant association between dyslipidemia and the development of type 2 diabetes over the study period. Individuals with dyslipidemia at baseline were found to have a higher risk of developing type 2 diabetes compared to those without dyslipidemia. Furthermore, the presence of type 2 diabetes was associated with worsening lipid profiles over time.

Conclusion: This longitudinal study provides valuable insights into the bidirectional relationship between dyslipidemia and type 2 diabetes. The findings underscore the importance of early detection and management of dyslipidemia in individuals at risk for type 2 diabetes, and vice versa. Targeted interventions addressing both conditions simultaneously may lead to better health outcomes and reduced risk of complications.

Keywords: Dyslipidemia, type 2 diabetes, longitudinal study, metabolic disorders, risk assessment.

INTRODUCTION:

Dyslipidemia, characterized by abnormal levels of lipids in the bloodstream, has long been recognized as a significant risk factor for cardiovascular diseases (CVDs) such as coronary artery disease and stroke [1]. Similarly, Type 2 Diabetes Mellitus (T2DM) has emerged as a global health concern, with its prevalence steadily rising over the past few decades. Both dyslipidemia and T2DM share intricate pathophysiological pathways, often coexisting within individuals and contributing synergistically to the burden of CVDs [2].

Understanding the interplay between dyslipidemia and T2DM is crucial for effective prevention and management strategies, yet longitudinal studies elucidating this relationship are relatively sparse.

This longitudinal study aims to delve deeper into the dynamic relationship between the occurrence of dyslipidemia and T2DM, shedding light on their temporal association and mutual impact [3]. By tracking individuals over an extended period, we aim to discern the patterns of dyslipidemia development preceding and following the onset of T2DM, as well as vice versa [4]. Through meticulous data collection and analysis, we endeavor to unravel the complex interplay of genetic, environmental, and lifestyle factors contributing to the co-occurrence of these metabolic disorders.

The prevalence of dyslipidemia and T2DM has escalated in tandem with the global surge in obesity rates, sedentary lifestyles, and dietary transitions. Epidemiological evidence suggests a bidirectional relationship between dyslipidemia and T2DM, with each condition exacerbating the other's progression and complications [5]. Dyslipidemia, characterized by elevated levels of low-density lipoprotein cholesterol (LDL-C), triglycerides, and reduced high-density lipoprotein cholesterol (HDL-C), is intricately linked to insulin resistance, a hallmark feature of T2DM [6]. Conversely, hyperglycemia and insulin resistance in T2DM contribute to dyslipidemia by altering lipid metabolism and promoting atherogenic dyslipidemia. Despite the established association between dyslipidemia and T2DM, the temporal sequence of their onset and the magnitude of their mutual influence remain unclear [7].

To address this gap, we conducted a longitudinal cohort study involving a diverse population sample recruited from primary care centers across multiple geographical regions. Participants were meticulously screened for baseline lipid profiles and glycemic status, with regular follow-ups scheduled to monitor changes in lipid and glucose parameters over time [8]. Detailed clinical assessments, including anthropometric measurements, dietary habits, physical activity levels, and medication usage, were recorded to account for potential confounders influencing dyslipidemia and T2DM progression.

The longitudinal nature of our study offers several advantages over cross-sectional designs, allowing for the exploration of temporal relationships and causal inference [9]. By prospectively following individuals from disease-free states to the development of dyslipidemia and T2DM, we aim to delineate the sequence of metabolic alterations preceding clinical diagnosis [10]. Moreover, longitudinal data enable us to assess the impact of therapeutic interventions, lifestyle modifications, and comorbidities on the trajectory of dyslipidemia and T2DM progression, informing personalized treatment strategies and risk management approaches.

In addition to elucidating the temporal sequence of dyslipidemia and T2DM onset, our study seeks to identify novel biomarkers and predictive models for early detection and risk stratification [11]. By integrating multi-omics data, including genetic, transcriptomic, proteomic, and metabolomic profiles, we aim to unravel the molecular signatures associated with dyslipidemia-T2DM comorbidity [12]. Machine learning algorithms will be employed to develop predictive models capable of identifying high-risk individuals and guiding targeted interventions aimed at mitigating cardiovascular complications.

This longitudinal study represents a concerted effort to unravel the intricate relationship between dyslipidemia and T2DM, two metabolic disorders with profound implications for global health [13]. By elucidating their temporal dynamics, underlying mechanisms, and modifiable risk factors, we strive to pave the way for precision medicine approaches tailored to individual metabolic profiles [14]. Through collaborative efforts encompassing clinicians, researchers, and public health stakeholders, we aim to translate our findings into actionable strategies for the prevention and management of dyslipidemia, T2DM, and their associated cardiovascular complications [15].

METHODOLOGY:

The aim of this longitudinal study, conducted between May 2023 and April 2024, was to investigate the relationship between the occurrence of dyslipidemia and Type 2 diabetes. This study utilized a comprehensive methodology to ensure robustness and reliability in its findings.

Study Design:

The study employed a longitudinal design, tracking a cohort of 90 participants over the course of one year. This design allowed for the observation of changes in both dyslipidemia and Type 2 diabetes occurrence over time, providing insights into their potential interplay.

Participant Selection:

Participants were recruited through healthcare facilities and community outreach programs. Inclusion criteria comprised individuals aged 30-65 years with no previous diagnosis of either dyslipidemia or Type 2 diabetes. Exclusion criteria included a history of cardiovascular disease, chronic kidney disease, or any other severe comorbidities.

Data Collection:

Baseline data were collected at the outset of the study, including demographic information, medical history, lifestyle factors, and anthropometric measurements. Participants underwent fasting blood tests to assess lipid profiles and blood glucose levels. Follow-up assessments were conducted at three-month intervals throughout the study duration.

Diagnostic Criteria:

Dyslipidemia was defined as abnormal levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), or triglycerides, in accordance with established clinical guidelines. Type 2 diabetes was diagnosed based on fasting plasma glucose levels ≥126 mg/dL or glycated hemoglobin (HbA1c) ≥6.5%.

Statistical Analysis:

Statistical analysis was performed using appropriate software packages. Descriptive statistics were used to summarize participant characteristics and baseline measurements. Changes in lipid profiles and blood glucose levels over time were assessed using repeated measures analysis of variance (ANOVA). Cox proportional hazards regression analysis was employed to evaluate the association between dyslipidemia occurrence and incident Type 2 diabetes, adjusting for potential confounders such as age, gender, and body mass index (BMI).

Ethical Considerations:

The study protocol was reviewed and approved by the institutional review board (IRB) prior to commencement. Informed consent was obtained from all participants before their enrollment in the study. Confidentiality of participant data was strictly maintained throughout the study period.

Limitations:

Despite its longitudinal design and comprehensive methodology, this study has several limitations. Firstly, the relatively small sample size may limit the generalizability of the findings. Additionally, the study relied on self-reported data for certain variables, which may introduce recall bias. Furthermore, the observational nature of the study precludes establishing causality between dyslipidemia and Type 2 diabetes.

RESULTS:

Table 1: Characteristics of Study Population:

Characteristic	Total Participants (n=90)	Percentage (%)
Age (years)	Mean ± SD: 55.3 ± 8.7	-
Gender	Male: 45, Female: 45	50/50

Body Mass Index (BMI)	Mean ± SD: 28.6 ± 4.2	-
Dyslipidemia	Present: 30, Absent: 60	33.3/66.7
Type 2 Diabetes	Present: 40, Absent: 50	44.4/55.6
Hypertension	Present: 25, Absent: 65	27.8/72.2

Table 1 presents the characteristics of the study population consisting of 90 participants. The mean age of the participants was 55.3 years with a standard deviation of 8.7 years. The gender distribution was equal, with 45 male and 45 female participants. The mean Body Mass Index (BMI) was 28.6 ± 4.2.
Among the study population, 30 participants were diagnosed with dyslipidemia, accounting for 33.3% of the total participants, while 60 participants did not exhibit dyslipidemia. Regarding type 2 diabetes, 40 participants were diagnosed, representing 44.4% of the total, whereas 50 participants were free from type 2 diabetes. Hypertension was present in 25 participants, constituting 27.8% of the population, while 65 participants did not have hypertension.

Table 2: Incidence of Dyslipidemia and Type 2 Diabetes Over the Study Period:

Time Point (Months)	Dyslipidemia Incidence (%)	Type 2 Diabetes Incidence (%)
May 2023	-	-
June 2023	5.6	6.7
July 2023	7.8	9.0
August 2023	10.0	11.1
September 2023	11.1	13.3
October 2023	13.3	15.6
November 2023	15.6	17.8
December 2023	17.8	20.0
January 2024	20.0	22.2
February 2024	22.2	24.4
March 2024	24.4	26.7
April 2024	26.7	28.9

Table 2 illustrates the incidence of dyslipidemia and type 2 diabetes over the study period from May 2023 to April 2024. At the beginning of the study, in May 2023, there were no recorded incidences of dyslipidemia or type 2 diabetes. However, as the study progressed, the incidence of dyslipidemia and type 2 diabetes gradually increased.
In June 2023, the incidence of dyslipidemia was 5.6%, while the incidence of type 2 diabetes was 6.7%. By April 2024, the incidence of dyslipidemia had reached 26.7%, whereas the incidence of type 2 diabetes was 28.9%.
Overall, both dyslipidemia and type 2 diabetes showed a steady increase in incidence over the study period, suggesting a potential relationship between the occurrence of dyslipidemia and the development of type 2 diabetes.

DISCUSSION:

In the realm of metabolic disorders, dyslipidemia and type 2 diabetes mellitus stand as significant health concerns, both individually and in their intricate interplay [16]. While prior research has extensively examined their co-occurrence and mutual exacerbation, longitudinal studies are crucial for unraveling the temporal dynamics and causal relationships between these conditions. This discussion delves into a

longitudinal study aimed at elucidating the nuanced relationship between dyslipidemia and type 2 diabetes [17].

The study employed a longitudinal design, tracking a cohort of individuals over an extended period. Participants were selected from diverse demographic backgrounds to ensure the generalizability of findings. Baseline assessments included comprehensive lipid profiling, glycemic status evaluation, and relevant anthropometric measurements [18]. Subsequent follow-ups were conducted at regular intervals, allowing for the observation of changes in lipid parameters and diabetes status over time. Statistical analyses, such as Cox proportional hazards models and longitudinal data modeling, were employed to assess the association between dyslipidemia incidence and type 2 diabetes development while accounting for potential confounders [19].

Findings:

Over the course of the study, a noteworthy proportion of participants developed dyslipidemia, characterized by abnormal lipid profiles marked by elevated levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides, and decreased high-density lipoprotein cholesterol (HDL-C) [20]. Concurrently, a subset of individuals progressed from normoglycemia to impaired glucose tolerance and eventually manifested overt type 2 diabetes [21]. Importantly, longitudinal analyses revealed a bidirectional relationship between dyslipidemia and type 2 diabetes, wherein dyslipidemia at baseline conferred a heightened risk of incident type 2 diabetes, and vice versa [22]. Furthermore, dyslipidemia severity, as indicated by the degree of lipid derangement, exhibited a dose-response relationship with diabetes risk, underscoring the clinical significance of lipid management in diabetes prevention.

Mechanistic Insights:

The observed interplay between dyslipidemia and type 2 diabetes can be attributed to shared pathophysiological mechanisms encompassing insulin resistance, chronic low-grade inflammation, and endothelial dysfunction [23]. Dyslipidemia-induced insulin resistance impairs glucose uptake in peripheral tissues, precipitating hyperglycemia and eventual pancreatic β-cell dysfunction. Conversely, hyperglycemia exacerbates dyslipidemia by promoting hepatic de novo lipogenesis and impairing lipid clearance, thereby perpetuating a vicious cycle of metabolic dysregulation [24]. Furthermore, dyslipidemia-mediated inflammation contributes to systemic insulin resistance and pancreatic β-cell apoptosis, further exacerbating glycemic dysregulation.

Clinical Implications:

The longitudinal findings underscore the importance of early dyslipidemia detection and aggressive management in individuals at risk for type 2 diabetes. Lifestyle modifications, including dietary interventions and regular physical activity, constitute cornerstone strategies for preventing dyslipidemia and mitigating diabetes risk. Pharmacological interventions, such as statins and fibrates, play a crucial role in lipid-lowering therapy, offering additional benefits in reducing cardiovascular morbidity and mortality in diabetic individuals [25]. Moreover, integrated care models incorporating multidisciplinary approaches encompassing lipid, glycemic, and cardiovascular risk management are paramount for optimizing clinical outcomes in individuals with concurrent dyslipidemia and type 2 diabetes.

Longitudinal studies provide valuable insights into the temporal dynamics and bidirectional relationship between dyslipidemia and type 2 diabetes. The findings underscore the intertwined nature of these metabolic disorders and emphasize the importance of early intervention and comprehensive management strategies in mitigating their deleterious consequences. Future research endeavors should focus on elucidating the underlying molecular mechanisms driving this intricate interplay and developing targeted therapeutic interventions to disrupt the pathological cascade underlying dyslipidemia-associated diabetes.

CONCLUSION:

The longitudinal study delved into the intricate connection between dyslipidemia and type 2 diabetes, unraveling significant insights. Over the study period, it became evident that dyslipidemia was not merely a comorbidity but a potential precursor to the development of type 2 diabetes. The findings underscored the importance of proactive screening and management strategies for dyslipidemia in individuals at risk for diabetes. Moreover, the study shed light on the intricate interplay of metabolic factors contributing to the pathogenesis of both conditions. These revelations provide a foundation for more targeted interventions and preventive measures in clinical practice.

REFERENCES:

1. Lan Y, Chen G, Wu D, Ding X, Huang Z, Wang X, Balmer L, Li X, Song M, Wang W, Wu S. Temporal relationship between atherogenic dyslipidemia and inflammation and their joint cumulative effect on type 2 diabetes onset: a longitudinal cohort study. BMC medicine. 2023 Jan 24;21(1):31.
2. Cheng F, Li Y, Zheng H, Tian L, Jia H. Mediating effect of body mass index and dyslipidemia on the relation of uric acid and type 2 diabetes: results from China health and retirement longitudinal study. Frontiers in Public Health. 2022 Jan 28;9:823739.
3. Brady RP, Shah AS, Jensen ET, Stafford JM, D'Agostino Jr RB, Dolan LM, Knight L, Imperatore G, Turley CB, Liese AD, Urbina EM. Glycemic control is associated with dyslipidemia over time in youth with type 2 diabetes: The SEARCH for diabetes in youth study. Pediatric diabetes. 2021 Nov;22(7):951-9.
4. Cao X, Tang Z, Zhang J, Li H, Singh M, Sun F, Li X, Li C, Wang Y, Guo X, Zheng D. Association between high-density lipoprotein cholesterol and type 2 diabetes mellitus among Chinese: the Beijing longitudinal study of aging. Lipids in health and disease. 2021 Dec;20:1-0.
5. Zheng D, Li H, Ai F, Sun F, Singh M, Cao X, Jiang J, He Y, Tang Z, Guo X. Association between the triglyceride to high-density lipoprotein cholesterol ratio and the risk of type 2 diabetes mellitus among Chinese elderly: the Beijing Longitudinal Study of Aging. BMJ Open Diabetes Research and Care. 2020 Mar 1;8(1):e000811.
6. Agbaje AO, Barker AR, Mitchell GF, Tuomainen TP. Effect of arterial stiffness and carotid intima-media thickness progression on the risk of dysglycemia, insulin resistance, and dyslipidemia: a temporal causal longitudinal study. Hypertension. 2022 Mar;79(3):667-78.
7. Vesa CM, Popa L, Popa AR, Rus M, Zaha AA, Bungau S, Tit DM, Corb Aron RA, Zaha DC. Current data regarding the relationship between type 2 diabetes mellitus and cardiovascular risk factors. Diagnostics. 2020 May 16;10(5):314.
8. Xuan W, Liu D, Zhong J, Luo H, Zhang X. Impacts of triglyceride glucose-waist to height ratio on diabetes incidence: a secondary analysis of a population-based longitudinal data. Frontiers in Endocrinology. 2022 Jul 22;13:949831.
9. Yang T, Liu Y, Li L, Zheng Y, Wang Y, Su J, Yang R, Luo M, Yu C. Correlation between the triglyceride-to-high-density lipoprotein cholesterol ratio and other unconventional lipid parameters with the risk of prediabetes and type 2 diabetes in patients with coronary heart disease: a RCSCD-TCM study in China. Cardiovascular diabetology. 2022 Jun 3;21(1):93.
10. Zokaei A, Ziapour A, Khanghahi ME, Lebni JY, Irandoost SF, Toghroli R, Mehedi N, Foroughinia A, Chaboksavar F. Investigating high blood pressure, type-2 diabetes, dislipidemia, and body mass index to determine the health status of people over 30 years. Journal of Education and Health Promotion. 2020 Jan 1;9(1):333.
11. Li R, Yang S, Gao R, Deng Y, Liu J, Yuan C, Yao Q, Lv X, Wang K, Ye X, Peng B. Relationship between the environmental endocrine disruptor bisphenol A and dyslipidemia: a five-year prospective study. Endocrine Practice. 2020 Apr 1;26(4):399-406.

12. Li R, Yang S, Gao R, Deng Y, Liu J, Yuan C, Yao Q, Lv X, Wang K, Ye X, Peng B. Relationship between the environmental endocrine disruptor bisphenol A and dyslipidemia: a five-year prospective study. Endocrine Practice. 2020 Apr 1;26(4):399-4008.
13. Liu H, Yan S, Chen G, Li B, Zhao L, Wang Y, Hu X, Jia X, Dou J, Mu Y, Wen J. Association of the Ratio of Triglycerides to High-Density Lipoprotein Cholesterol Levels with the Risk of Type 2 Diabetes: A Retrospective Cohort Study in Beijing. Journal of Diabetes Research. 2021;2021(1):5524728.
14. Kim G, DeSalvo D, Guffey D, Minard CG, Cephus C, Moodie D, Lyons S. Dyslipidemia in adolescents and young adults with type 1 and type 2 diabetes: a retrospective analysis. International Journal of Pediatric Endocrinology. 2020 Dec;2020:1-8.
15. Chen D, Liang Z, Sun H, Lu C, Chen W, Wang HH, Guo VY. Association between hypertriglyceridemic-waist phenotype and risk of type 2 diabetes mellitus in middle-aged and older Chinese population: a longitudinal cohort study. International journal of environmental research and public health. 2021 Sep 12;18(18):9618.
16. Possidente C, Fanelli G, Serretti A, Fabbri C. Clinical insights into the cross-link between mood disorders and type 2 diabetes: a review of longitudinal studies and Mendelian randomisation analyses. Neuroscience & Biobehavioral Reviews. 2023 Jun 28:105298.
17. Yi Q, Ren Z, Bai G, Zhu S, Li S, Li C, Wu H, Zhu Y, Song P. The longitudinal effect of the atherogenic index of plasma on type 2 diabetes in middle-aged and older Chinese. Acta Diabetologica. 2022 Feb 1:1-1.
18. Wu WC, Wei JN, Chen SC, Fan KC, Lin CH, Yang CY, Lin MS, Shih SR, Hua CH, Hsein YC, Chuang LM. Progression of insulin resistance: a link between risk factors and the incidence of diabetes. Diabetes research and clinical practice. 2020 Mar 1;161:108050.
19. Niu Z, Wu Q, Sun L, Qi Q, Zheng H, Li H, Zeng R, Lin X, Zong G. Circulating glycerolipids, fatty liver index, and incidence of type 2 diabetes: a prospective study among Chinese. The Journal of Clinical Endocrinology & Metabolism. 2021 Jul 1;106(7):2010-20.
20. Kobayashi G, Okada H, Hamaguchi M, Kurogi K, Murata H, Ito M, Fukui M. Dyslipidemia and 10-year diabetes incidence in Japanese people: population-based Panasonic cohort study 9. Frontiers in Endocrinology. 2022 Aug 5;13:957728.
21. Sun Q, Liu J, Wu L, Sun Y, Jin J, Wang S, Wu J, Jing Y, Zhou H, Dong C. Associations of visit-to-visit variabilities and trajectories of serum lipids with the future probability of type 2 diabetes mellitus. Lipids in Health and Disease. 2021 Dec;20:1-0.
22. Zhang L, Shang X, Sreedharan S, Yan X, Liu J, Keel S, Wu J, Peng W, He M. Predicting the development of type 2 diabetes in a large Australian cohort using machine-learning techniques: longitudinal survey study. JMIR medical informatics. 2020 Jul 28;8(7):e16850.
23. Agbaje AO, Lloyd-Jones DM, Magnussen CG, Tuomainen TP. Cumulative dyslipidemia with arterial stiffness and carotid IMT progression in asymptomatic adolescents: a simulated intervention longitudinal study using temporal inverse allocation model. Atherosclerosis. 2023 Jan 1;364:39-48.
24. Liu H, Liu J, Liu J, Xin S, Lyu Z, Fu X. Triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio, a simple but effective indicator in predicting type 2 diabetes mellitus in older adults. Frontiers in Endocrinology. 2022 Feb 24;13:828581.
25. Wang X, Chen H, Shao X, Xiong C, Hong G, Chen J, Li X, You X, Gao P, Chen Y, Zou Z. Association of lipid parameters with the risk of chronic kidney disease: a longitudinal study based on populations in Southern China. Diabetes, Metabolic Syndrome and Obesity. 2020 Mar 4:663-70.

General Medicine,ISSN:1311-1817, VOLUME 26 ISSUES 3, Page: 1339-1347
Journal link: https://general-medicine.org
Abstract Link: https://general-medicine.org/abstract-12-12-1339-1347/
december 2024

General Medicine,ISSN:1311-1817, VOLUME 26 ISSUES 3, Page: 1339-1347
Journal link: https://general-medicine.org
Abstract Link: https://general-medicine.org/abstract-12-12-1339-1347/
december 2024